Cubresa, Inc.

Cubresa, Inc. develops advanced imaging solutions, specializing in clinical and preclinical Positron Emission Tomography (PET) inserts for Magnetic Resonance Imaging (MRI), enhancing imaging capabilities for medical research and diagnostics. Cubresa, Inc. is focused on the design and development of innovative imaging systems, with its headquarters located in Winnipeg, Canada.

The company was founded by James Schellenberg, who has a history in medical technology innovation. In June 2013, Cubresa raised USD 0. 5 million in Series A funding from a group of angel investors, which marked a significant milestone in its funding journey. The company has made one deal to date.

Cubresa Inc. specializes in creating advanced imaging technologies, particularly in developing clinical and preclinical Positron Emission Tomography (PET) inserts for Magnetic Resonance Imaging (MRI). Their flagship product, the BrainPET insert, integrates with 3T MRI scanners to facilitate concurrent PET and MR imaging. This system enhances spatial resolution and sensitivity compared to conventional imaging systems, allowing for in-depth visualization of biochemical processes in neurology and oncology.

Additionally, Cubresa offers the NuPET and NuPET Bio systems, which are adaptable for various MRI environments or as standalone PET imaging solutions. Their primary clients include leading universities, hospitals, and pharmaceutical companies across North America and Europe, focusing on research areas such as epilepsy, major depressive disorder, and stroke analysis. Cubresa generates revenue primarily through the direct sale and potential licensing of its proprietary imaging technologies, including the BrainPET and NuPET systems. The business model consists of B2B transactions with research institutions and medical facilities, which may involve partnership agreements or direct purchases.

Pricing is generally customized according to client needs, and revenue streams can also come from installations and maintenance services, reflecting the substantial investments in advanced medical technologies. Cubresa plans to leverage its recent funding from June 2013 to further develop and enhance its product offerings. The company is focusing on launching new products that build upon their current imaging technologies, although specific release dates have not been disclosed. Additionally, there are intentions to expand into new geographic markets, specifically targeting research institutions and medical facilities in emerging economies to enhance their market presence.

The funding will support these initiatives by facilitating research and development, ensuring Cubresa continues to innovate in medical imaging solutions.